Table 3.
Adequacy of glycaemic management in diabetic patients on follow-up at JUSH, November 2009
| FBS | ||||||
|---|---|---|---|---|---|---|
| Treatment categories | Average FBS, mg/dl | ≤ 130 mg/dl | > 130 mg/dl | P-value | ||
| N | % | N | % | |||
| Pharmacotherapeutic options | ||||||
| Insulin alone | 170.8 | 37 | 23.6 | 120 | 76.4 | |
| Insulin and OGLA | 190.3 | 3 | 23.1 | 10 | 76.9 | 0.0006 |
| One OGLA | 152.7 | 28 | 41.8 | 39 | 58.2 | |
| Both OGLA | 188.7 | 15 | 22.4 | 59 | 77.6 | |
| Doses of drugs | ||||||
| Insulin | ||||||
| < 1IU/Kg/d | 167.7 | 36 | 25.5 | 105 | 74.5 | 0.175 |
| ≥ 1IU/kg/d | 194.5 | 4 | 13.8 | 25 | 86.2 | |
| Glibenclamide (G) | ||||||
| < 20 mg/d | 149.4 | 30 | 50.0 | 30 | 50.0 | 0.0001 |
| ≥ 20 mg/d | 190.0 | 11 | 15.1 | 62 | 84.9 | |
| Metformin(M) | ||||||
| < 1000 mg/d | 163.1 | 15 | 38.5 | 24 | 61.5 | 0.001 |
| ≥ 1000 mg/d | 204.3 | 5 | 8.9 | 52 | 91.1 | |
| Glibenclamide + metformin | ||||||
| G < 20 mg/d or M < 1000 mg/d | 168.1 | 12 | 36.4 | 21 | 63.6 | 0.005 |
| G ≥ 20 mg/d & M ≥ 1000 mg/d | 203.3 | 4 | 9.5 | 38 | 90.5 | |
| Modification of glycaemic treatment during the last 3 visits | ||||||
| Yes | 16* | 19.0 | 70 | 30.7 | ||
| No | 68 | 81.0 | 158 | 69.3 | ||
* In 13 of these patients treatment modification was for low FBS or symptoms of hypoglycemia.